Filing Details
- Accession Number:
- 0000891293-22-000045
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-09-20 16:59:57
- Reporting Period:
- 2022-06-30
- Accepted Time:
- 2022-09-20 16:59:57
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 891293 | Cti Biopharma Corp | CTIC | Pharmaceutical Preparations (2834) | 911533912 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1276750 | David Kirske | C/O Cti Biopharma Corp. 3101 Western Ave., Suite 800 Seattle WA 98121 | Evp, Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-06-30 | 9,516 | $2.12 | 16,913 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2022-09-16 | 22,592 | $0.95 | 39,505 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-09-16 | 22,592 | $6.02 | 16,913 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2022-09-16 | 22,592 | $0.00 | 22,592 | $0.95 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 467,408 | 2029-02-19 | No | 4 | M | Direct |
Footnotes
- Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan.
- This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
- One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.
Billionaire Hedge Funds
